Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
GT Biopharma ( (GTBP) ) has shared an announcement.
On May 12, 2025, GT Biopharma, Inc. entered into a Securities Purchase Agreement for a private placement of its Series L 10% Convertible Preferred Stock and accompanying warrants, raising $5.45 million with potential for additional funding through Greenshoe Rights. This strategic financial move is aimed at enhancing the company’s capital structure and market positioning, with implications for shareholder approval and regulatory compliance through registration and voting agreements.
The most recent analyst rating on (GTBP) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on GT Biopharma stock, see the GTBP Stock Forecast page.
Spark’s Take on GTBP Stock
According to Spark, TipRanks’ AI Analyst, GTBP is a Underperform.
GT Biopharma’s overall stock score reflects significant financial challenges, including a lack of revenue and continuous losses, which are compounded by negative equity and reliance on external financing. While technical indicators are neutral, the valuation metrics highlight the absence of earnings and dividends. These factors, combined with a lack of any notable earnings call or corporate events, result in a low overall score.
To see Spark’s full report on GTBP stock, click here.
More about GT Biopharma
GT Biopharma, Inc. operates in the biopharmaceutical industry, focusing on the development and commercialization of innovative therapeutic products. The company primarily engages in creating treatments for cancer and other serious diseases, leveraging its proprietary technology platforms.
Average Trading Volume: 477,313
Technical Sentiment Signal: Strong Sell
Current Market Cap: $5.83M
See more data about GTBP stock on TipRanks’ Stock Analysis page.